Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide

Hippocampal Stratum Oriens Somatostatin-Positive Cells Undergo CB1-Dependent Long-Term Potentiation and Express Endocannabinoid Biosynthetic Enzymes

(2019) Lindsey Friend et al.   MOLECULES

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers

(2018) Viktoria Moschetti et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span

(2018) Neema S. Patel et al.   NEUROBIOLOGY OF AGING

A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers

(2017) Katja Boland et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Endocannabinoid modulation of dopamine neurotransmission

(2017) Dan P. Covey et al.   NEUROPHARMACOLOGY

Different phosphodiesterases (PDEs) regulate distinct phosphoproteomes during cAMP signaling

(2017) Paul M. Epstein   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STUDY DESIGN AND CHARACTERISTICS OF TWO PHASE II PROOF-OF-CONCEPT CLINICAL TRIALS OF THE PDE9 INHIBITOR BI 409306 IN EARLY ALZHEIMER'S DISEASE

(2016) Glen Wunderlich et al.   Alzheimers & Dementia

Natriuretic peptides in the central nervous system: Novel targets for cognitive impairment

(2016) Simin Mahinrad et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease

(2016) Tao Su et al.   Scientific Reports

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A

(2016) M S Alexander et al.   Translational Psychiatry

Application of neurophysiological biomarkers for Huntington's disease: Evaluating a phosphodiesterase 9A inhibitor

(2015) Dávid Nagy et al.   EXPERIMENTAL NEUROLOGY

Facilitation of Corticostriatal Transmission following Pharmacological Inhibition of Striatal Phosphodiesterase 10A: Role of Nitric Oxide-Soluble Guanylyl Cyclase-cGMP Signaling Pathways

(2015) F. E. Padovan-Neto et al.   JOURNAL OF NEUROSCIENCE

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

(2015) Dong I. Lee et al.   NATURE

A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer’s Disease

(2014) Elias Schwam et al.   Current Alzheimer Research

PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition

(2014) Katja S. Kroker et al.   NEUROBIOLOGY OF AGING

A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo

(2013) Mark J Hunt et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders

(2012) Patrick R. Verhoest et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP

(2012) Katja S. Kroker et al.   NEUROPHARMACOLOGY

The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task

(2011) Joshua D. Vardigan et al.   JOURNAL OF NEUROGENETICS

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

(2011) P.H. Hutson et al.   NEUROPHARMACOLOGY

Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues

(2010) Viktor Lakics et al.   NEUROPHARMACOLOGY

PDE9A-mediated regulation of cGMP: Developing a biomarker for a novel therapy for Alzheimer's disease

(2009) Christopher J. Schmidt et al.   Alzheimers & Dementia

Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy

(2009) Patrick R. Verhoest et al.   JOURNAL OF MEDICINAL CHEMISTRY

Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown

(2009) Miles D. Houslay   TRENDS IN BIOCHEMICAL SCIENCES

Concepts of neural nitric oxide-mediated transmission

(2008) John Garthwaite   EUROPEAN JOURNAL OF NEUROSCIENCE

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

(2008) C. J. Schmidt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents

(2008) F. Josef van der Staay et al.   NEUROPHARMACOLOGY

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background

(2007) Judith A. Siuciak et al.   NEUROPHARMACOLOGY

Natriuretic peptides and their receptors in the central nervous system

(2007) Li-Hui Cao et al.   PROGRESS IN NEUROBIOLOGY